In recent decades, parathyroid hormone-related analogues (e.g., teriparatide and abaloparatide) [19,21] and anti-sclerostin agents (e.g., romosozumab) [20] have also been tested as anabolic therapies for osteoporosis, especially in individuals who are at high risk of fragility fractures [17]. Here, SOST is linked to osteoporosis.